Medication Profile—Community Pharmacy
Patient Name: Marjorie Ask
Race: Caucasian
Address: 3541 Perhaps St.
Height: 5'5”
Age: 60
Weight: 113 lb
Gender: F
Allergies: NKA

Diagnosis
Hip dislocation, essential hypertension, hypothyroidism, Parkinson's disease, osteoporosis, neurotic disorders, and anxiety

Medication record
 
Date
RX No
Name and Strength
Route
Quantity
Sig
1.
7/12
13311
Coumadin® 2 mg
PO
30
i noon
2.
7/12
13312
Synthroid® 100 mg
PO
30
i qd
3.
7/17
13314
Norvasc® 5 mg
PO
30
i qd
4.
8/28
13315
Sinemet® CR 50/200
PO
30
i bid
5.
8/28
13316
Fosamax® 70 mg
PO
4
i qwk
6.
9/20
13317
Neurontin® 300 mg
PO
90
iii qhs
7.
9/20
13318
Os-Cal® 500 + vit D 200 mg
PO
30
i bid
8.
11/11
13319
Niferex® 150 mg
PO
30
i qd
9.
11/15
13320
Colace® 100 mg
PO
30
i qd
10.
11/15
13321
Xanax® 0.25 mg
PO
90
i tid
 
Use the patient profile above to answer the following questions.

1.
The generic name for Niferex®-150 is
A.
Multiple vitamins
B.
Iron polysaccharide complex
C.
Ferrous sulfate
D.
Ferrous gluconate
E.
Ferrous fumarate


2.
You are aware that Ms. Ask is currently taking Neurontin® and she has asked you to recommend a good antacid for her gastritis. Which of the following recommendations should you make to her as her pharmacist?
I. Take the Neurontin® at least 2 hours after taking the antacid
II. Do not take antacids while you are taking Neurontin®
III. Take Tagamet® instead
A.
I only
B.
II only
C.
III only
D.
I and III
E.
II and III


3.
The most likely reason for administration of Neurontin® in this patient is
A.
Partial seizures
B.
Neurotic disorder
C.
Chronic pain
D.
Essential hypertension
E.
Parkinson's disease


4.
Active ingredients for Sinemet® include?
I. Levodopa
II. Carbidopa
III. Levocarnitine
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


5.
Clinical characteristics of idiopathic Parkinson's disease include all of the following EXCEPT
A.
Bradykinesia
B.
Dementia
C.
Bradycardia
D.
Rigidity
E.
Dysphagia


6.
Which of the following medications can extend the duration of action of levodopa and permit the reduction of levodopa dose?
I. Symmetrel®
II. Eldepryl®
III. CogentinTM
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I, II, and III


7.
Treatment alternatives that can be used in patients with Parkinson's disease that are unresponsive or allergic to levodopa include
I. Parlodel®
II. Eldepryl®
III. Lodosyn®
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


8.
Treatment options that would not be available to Ms. Ask if she were taking Demerol include
I. Eldepryl®
II. Parlodel®
III. Symmetrel®
A.
I only
B.
II only
C.
III only
D.
I and II
E.
II and III


9.
If Ms. Ask developed allergy to Xanax®, treatment options for her would include
I. BuSpar®
II. Ativan®
III. Benylin®
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I and III


10.
Antianxiety drugs that are not generally recommended for immediate relief of anxiety because of their slow onset of action include
I. Ativan®
II. Serax®
III. Centrax
A.
I only
B.
II only
C.
III only
D.
I and II
E.
I, II, and III


STOP This is the end of the test. When you have completed all the questions and reviewed your answers, press the button below to grade the test.